Autopsy report · NCT05291390

Pyronaridine in Acute Myeloid Leukemia (AML)

“Change of protocol”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 200 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2

Sponsor

Armaceutica, Inc.

Sponsor type

Industry

Conditions

Acute Myeloid Leukemia (AML); Acute Lymphoblastic Leukemia (ALL)

Interventions

Pyronaridine Tetraphosphate

Participants

200 (planned, not actual)

Sites

1

Countries

Senegal

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.